scholarly journals PMP(Porphyrin-Micelle-PSMA) Nanoparticles for Photoacoustic and Ultrasound Signal Amplification in Mouse Prostate Cancer Xenografts

Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1636
Author(s):  
Daehyun Kim ◽  
Wonkook Han ◽  
Jin Ho Chang ◽  
Hak Jong Lee
Keyword(s):  
Cancer Diagnosis ◽  
Signal Amplification ◽  
Xenograft Model ◽  
Prostate Specific Membrane Antigen ◽  
Mouse Prostate ◽  
Great Progress ◽  
Ultrasound Signal ◽  
The One ◽  
Specific Membrane

Photoacoustic (PA) imaging is used widely in cancer diagnosis. However, the availability of PA agents has not made great progress due to the limitations of the one currently in use, porphyrin. Porphyrin–Micelle (PM), developed by synthesizing porphyrin and PEG-3.5k, confirmed the amplification of the PA agent signal, and added binding affinity in an LNCaP model by attaching prostate-specific membrane antigen PSMA. Compared to the previously used porphyrin, a superior signal was confirmed, and the potential of PMP was confirmed when it showed a signal superior to that of hemoglobin at the same concentration. In addition, in the in vivo mouse experiment, it was confirmed that the signal in the LNCaP xenograft model was stronger than that in the PC-3 xenograft model, and the PMP signal was about three times higher than that of PM and porphyrin.

The Role of Prostate Specific Membrane Antigen and Pepsinogen C Tissue Expression as an Adjunctive Method to Prostate Cancer Diagnosis

2009 ◽  
Vol 181 (2) ◽  
pp. 594-600 ◽  
Author(s):  
Alberto A. Antunes ◽  
Kátia R. Leite ◽  
Juliana M. Sousa-Canavez ◽  
Luiz H. Camara-Lopes ◽  
Miguel Srougi
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Tissue Expression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Diagnosis ◽  
Pepsinogen C ◽  
Specific Membrane

scholarly journals 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

2010 ◽  
Vol 51 (8) ◽  
pp. 1293-1300 ◽  
Author(s):  
J. P. Holland ◽  
V. Divilov ◽  
N. H. Bander ◽  
P. M. Smith-Jones ◽  
S. M. Larson ◽  
...  
Keyword(s):  
Antigen Expression ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Srikanth Boinapally ◽  
Hye-Hyun Ahn ◽  
Bei Cheng ◽  
Mary Brummet ◽  
Hwanhee Nam ◽  
...  
Keyword(s):  
Specific Antigen ◽  
Prostate Specific Membrane Antigen ◽  
Toxicity Profile ◽  
Microtubule Inhibitor ◽  
Promising Target ◽  
Significant Survival ◽  
Targeting Ability ◽  
Immunocompetent Mice ◽  
Specific Membrane

AbstractProstate-specific membrane antigen (PSMA) is a promising target for the treatment of advanced prostate cancer (PC) and various solid tumors. Although PSMA-targeted radiopharmaceutical therapy (RPT) has enabled significant imaging and prostate-specific antigen (PSA) responses, accumulating clinical data are beginning to reveal certain limitations, including a subgroup of non-responders, relapse, radiation-induced toxicity, and the need for specialized facilities for its administration. To date non-radioactive attempts to leverage PSMA to treat PC with antibodies, nanomedicines or cell-based therapies have met with modest success. We developed a non-radioactive prodrug, SBPD-1, composed of a small-molecule PSMA-targeting moiety, a cancer-selective cleavable linker, and the microtubule inhibitor monomethyl auristatin E (MMAE). SBPD-1 demonstrated high binding affinity to PSMA (Ki = 8.84 nM) and selective cytotoxicity to PSMA-expressing PC cell lines (IC50 = 3.90 nM). SBPD-1 demonstrated a significant survival benefit in two murine models of human PC relative to controls. The highest dose tested did not induce toxicity in immunocompetent mice. The high specific targeting ability of SBPD-1 to PSMA-expressing tumors and its favorable toxicity profile warrant its further development.

scholarly journals Prostate-Specific Membrane Antigen (PSMA) Promotes Angiogenesis of Glioblastoma Through Interacting With ITGB4 and Regulating NF-κB Signaling Pathway

2021 ◽  
Vol 9 ◽  
Author(s):  
Yang Gao ◽  
Hui Zheng ◽  
Liangdong Li ◽  
Mingtao Feng ◽  
Xin Chen ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Conditioned Medium ◽  
Poor Prognosis ◽  
Umbilical Vein ◽  
Tube Formation ◽  
Prostate Specific Membrane Antigen ◽  
Umbilical Vein Endothelial Cells ◽  
Specific Membrane

BackgroundGlioblastoma multiforme (GBM) is the most common primary malignant tumor in the central nervous system (CNS), causing the extremely poor prognosis. Combining the role of angiogenesis in tumor progression and the role of prostate-specific membrane antigen (PSMA) in angiogenesis, this study aims to explore the functions of PSMA in GBM.MethodsClinical GBM specimens were collected from 60 patients who accepted surgical treatment in Fudan University Shanghai Cancer Center between January 2018 and June 2019. Immunohistochemical staining was used to detect PSMA and CD31 expression in GBM tissues. Prognostic significance of PSMA was evaluated by bioinformatics. Human umbilical vein endothelial cells (HUVECs) transfected with PSMA overexpression plasmids or cultured with conditioned medium collected based on GBM cells, were used for CCK8, Transwell and tube formation assays. High-throughput sequencing and immunoprecipitation were used to explore the underlying mechanism. Furthermore, the in vivo experiment had been also conducted.ResultsWe demonstrated that PSMA was abundantly expressed in endothelium of vessels of GBM tissues but not in vessels of normal tissues, which was significantly correlated with poor prognosis. Overexpression of PSMA could promotes proliferation, invasion and tube formation ability of human umbilical vein endothelial cells (HUVECs). Moreover, U87 or U251 conditioned medium could upregulated PSMA expression and induce similar effects on phenotypes of HUVECs, all of which could be partially attenuated by 2-PMPA treatment. The mechanistic study revealed that PSMA might promote angiogenesis of GBM through interacting with Integrin β4 (ITGB4) and activating NF-κB signaling pathway. The in vivo growth of GBM could be alleviated by the treatment of 2-PMPA.ConclusionThis study identified PSMA as a critical regulator in angiogenesis and progression of GBM, which might be a promising therapeutic target for GBM treatment.

Sign in / Sign up

Export Citation Format

Share Document